Free Trial

Aadi Bioscience Q4 2022 Earnings Report

Aadi Bioscience logo
$2.36 -0.03 (-1.26%)
(As of 01:37 PM ET)

Aadi Bioscience EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Aadi Bioscience Revenue Results

Actual Revenue
$5.23 million
Expected Revenue
$4.58 million
Beat/Miss
Beat by +$650.00 thousand
YoY Revenue Growth
N/A

Aadi Bioscience Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

The #1 Coin for November 2024 (Ad)

‘Gift’ Yourself a Potential 10,000% Win! #1 Crypto to Buy Before 2025 REVEALED!

Click here to get all the details on this crypto coin now.

Aadi Bioscience Earnings Headlines

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 12.7%
US Penny Stocks Under $90M Market Cap To Watch
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Aadi Bioscience Reports Q3 2024 Earnings and Growth
See More Aadi Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aadi Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aadi Bioscience and other key companies, straight to your email.

About Aadi Bioscience

Aadi Bioscience (NASDAQ:AADI), a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

View Aadi Bioscience Profile

More Earnings Resources from MarketBeat

Upcoming Earnings